EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›ALBT

ALBT

Avalon GloboCare Corp.

Next earnings Aug 12, 2026

Sell
$0.28
▼ -6.00%
$0.28▼ -89.82%
over 1Y
L $0.28EODHDH $3.46
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-6.0%
1W-22.3%
1M-19.9%
3M-43.8%
YTD-77.4%
1Y-89.8%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Sell
Quality
F
Valuation
Fair value
Filings
Flagged
Sell
Conviction
Horizon
Medium (3–12mo)

Revenue fell -100.0% YoY.

Revenue (FY2025) $0.00 · FY2025

Avalon GloboCare Corp. shows $0.00 in FY2025 revenue (-100.0% YoY), and -197.8% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$1.39M$1.20M$1.26M$1.33M$0.00
Gross profit$415K$273K———
Operating income-$8.83M-$8.79M-$15.8M-$4.84M-$7.59M
Net income-$9.09M-$11.9M-$16.7M-$7.90M-$18.3M
Diluted EPS-$1.07-$1.28-$23.80-$8.44-$5.64
Net margin-653.5%-992.4%-1330.5%-592.7%—

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$6.15M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-807.1%
FCF yield-203.4%

Quality & risk

ROIC (est.)-45.3%
Free cash flow-$4.60M
Total debt$4.00M
Net cash-$3.89M
Altman Z-Score-7.96 distress
Piotroski F-Score1/7

Capital returns

Buyback yield23.1%
Dividend yield (est.)—
Shareholder yield23.1%
Shares Δ YoY+385.8%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Red flag in recent filings — delisting notice (2026-04-17). Worth a closer look.
  1. 8-K Shareholder vote2026-06-09
  2. 8-K Officer / director change2026-06-04
  3. 10-Q Quarterly report2026-05-11
  4. 8-K Other event2026-04-21
  5. 8-K/A Amended 8-K2026-04-21
  6. 8-K Delisting notice2026-04-17
  7. DEF 14A Proxy statement2026-04-17
  8. S-1 Securities registration2026-04-08
  9. 8-K Material event2026-04-02

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-092026-06-09open ↗8-KPeriod ending 2026-06-012026-06-04open ↗SCHEDULE 13GFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-11open ↗8-K/APeriod ending 2026-02-182026-04-21open ↗8-KPeriod ending 2026-04-212026-04-21open ↗EFFECTFiling2026-04-20open ↗424B3Filing2026-04-20open ↗ARSPeriod ending 2025-12-312026-04-17open ↗DEFA14AFiling2026-04-17open ↗DEF 14APeriod ending 2026-06-092026-04-17open ↗8-KPeriod ending 2026-04-152026-04-17open ↗

Quality score

F
ValueGrowthProfitHealthMom.
Value—
GrowthF
ProfitabilityF
Financial healthC
Momentum—
  • ✗Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$0.00
-100.0% YoY
Net margin
—
ROE
-197.8%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$0.00-100.0%
Net income-$18.3M-131.1%
Gross profit$273K-34.2%
Operating income-$7.59M-56.8%
Diluted EPS-$5.64+33.2%
Cash & equivalents$109K-95.9%
Total assets$23.4M+11.5%
Total liabilities$14.2M+2.1%
Stockholders' equity$9.23M+30.0%
L/E: 1.54x

Frequently asked

Is Avalon GloboCare Corp. (ALBT) a buy?
ALBT currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Revenue fell -100.0% YoY.
What is Avalon GloboCare Corp.'s quality score?
ALBT scores 32.38461538461539/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001630212, latest 10-Q filed 2026-05-11) · EODHD · as of 6/23/2026, 12:42:40 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2022-08-05
Lu Wenzhao
Director
Award449K @ $0.78$350K
2022-07-18
Lu Wenzhao
Director
Award4.44M @ $0.65$2.89M
2021-12-21
Lu Wenzhao
Director
Award2.40M @ $1.25$3.00M
2020-04-01
Lu Wenzhao
Director
Buy645K @ $1.55$1000K

Earnings history

beat/miss · move
2023-04-27—▲ +6.70%8-K ↗
2018-11-14—▲ +0.47%8-K ↗
2018-08-15—▲ 0.00%8-K ↗
2018-05-14—▲ 0.00%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Avalon GloboCare Announces Closing of up to $9.75 Million Private Placement Priced At-the-Market under Nasdaq RulesBullish
globenewswire.com· 2026-02-27
Avalon subsidiary accepted into AMD AI developer programBullish
finance.yahoo.com· 2026-02-27
Avalon GloboCare Announces up to $9.75 Million Private Placement Priced At-the-Market under Nasdaq RulesBullish
globenewswire.com· 2026-02-27
This Penny Stock Is Getting a Major Boost From AMD Today. Should You Buy In?Bullish
finance.yahoo.com· 2026-02-26
BC-Most Active StocksBullish
finance.yahoo.com· 2026-02-26
Avalon GloboCare’s Subsidiary Accepted into AMD AI Developer Program to Advance Next-Generation Media InfrastructureBullish
finance.yahoo.com· 2026-02-26

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score32 vs 67
Revenue growth-100.0% vs 7.1%
Net margin— vs 10.5%
Return on equity-197.8% vs 12.3%
P/E— vs 25.5